CardioMetaIQ integrates a nine-state coupled ODE — forced by a GLP-1 drug fraction and calibrated to published phase-3 anchors — to project one patient's cardiometabolic trajectory across 52 weeks.
Set a phenotype and a candidate agent; watch the projected 52-week response and trajectories update. This is an illustrative emergent-map surrogate of the full twin — directional, not diagnostic.